Protagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ET
July 06, 2021 06:17 ET | Protagenic Therapeutics, Inc.
NEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders,...
VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients
September 25, 2018 08:00 ET | VBI Vaccines, Inc.
Independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of study without modificationIntermediate-dose study arm: enrollment complete Initial immunologic data from low...
CRISPR Therapeutics Announces Collaboration with Massachusetts General Hospital to Research Use of CRISPR/Cas9 in T Cell Cancer Therapies
August 22, 2017 07:30 ET | CRISPR Therapeutics AG
ZUG, Switzerland and CAMBRIDGE, Mass., Aug. 22, 2017 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Exclusive License to Advanced CRISPR Genome Editing Technology from Massachusetts General Hospital
August 03, 2016 08:00 ET | Editas Medicine
-- License to Engineered Forms of Cas9 Nuclease Includes High-Fidelity Cas9 and Cas9 PAM Variants -- CAMBRIDGE, Mass., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a...
Massachusetts Genera
Massachusetts General Hospital Improves Communication in Its Operating Rooms With Vocera
December 09, 2015 08:00 ET | Vocera Communications
SAN JOSE, Calif., Dec. 09, 2015 (GLOBE NEWSWIRE) -- Vocera Communications (NYSE:VCRA), the leading mobile healthcare communications company, announced today that Massachusetts General Hospital (MGH)...